Whether HOXA5 promotes breast cancer progression by enhancing glycolysis suggests that, based on molecular docking experiments, Artesunate could inhibit the aggravation of malignant phenotypes through lncRNA TUG1-mediated glycolysis suppression [26]. Here, TUG1 is linked to breast carcinoma.